<div id="readability-page-1"><p>Voya Investment Management LLC lowered its stake in shares of  Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 91.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,797 shares of the biotechnology company's stock after selling 303,855 shares during the quarter. Voya Investment Management LLC's holdings in Viking Therapeutics were worth $704,000 as of its most recent filing with the Securities and Exchange Commission.</p><div><p><span></span><span>Get <strong>Viking Therapeutics</strong> alerts:</span></p></div><ul><li>Viking Therapeutics: High Risk, High Reward Play</li></ul><p>Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Jump Financial LLC acquired a new stake in  Viking Therapeutics in the second quarter valued at $12,201,000.  Norges Bank acquired a new position in shares of  Viking Therapeutics during the 2nd quarter worth about $46,846,000.  Wealth Management Associates Inc. purchased a new position in shares of  Viking Therapeutics in the 1st quarter valued at about $241,000.  Kingstone Capital Partners Texas LLC purchased a new position in shares of  Viking Therapeutics in the 2nd quarter valued at about $1,367,000.  Finally, Marex Group plc acquired a new stake in shares of  Viking Therapeutics during the 2nd quarter worth about $983,000. 76.03% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Viking Therapeutics Trading Down 0.4%</h2><p>VKTX stock opened at $35.18 on Thursday. The firm has a 50 day moving average of $36.46 and a 200-day moving average of $32.15. The company has a market cap of $3.98 billion, a price-to-earnings ratio of -16.59 and a beta of 0.65. Viking Therapeutics, Inc. has a 12-month low of $18.92 and a 12-month high of $43.55. </p><ul><li>Biotech Breakouts: 3 Stocks With Massive Upside Potential</li></ul><p>Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its earnings results on Wednesday, October 22nd. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.14). During the same quarter in the previous year, the firm posted ($0.22) EPS. Viking Therapeutics's revenue for the quarter was up .0% compared to the same quarter last year.  Sell-side analysts forecast that  Viking Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year. </p><h2>Insider Activity</h2><p>In other news, Director Charles A. Rowland, Jr. sold 60,000 shares of Viking Therapeutics stock in a transaction on Monday, October 27th. The stock was sold at an average price of $35.57, for a total value of $2,134,200.00. Following the completion of the sale, the director owned 30,000 shares of the company's stock, valued at $1,067,100. The trade was a 66.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CFO Greg Zante sold 6,185 shares of the company's stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $35.00, for a total transaction of $216,475.00. Following the transaction, the chief financial officer directly owned 173,592 shares of the company's stock, valued at $6,075,720. This trade represents a 3.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 111,359 shares of company stock valued at $3,932,155 over the last quarter. Insiders own  4.10% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><ul><li>3 Biotech Stocks to Watch: Iovance, Neurocrine &amp; Viking</li></ul><p>Several analysts have recently weighed in on VKTX shares. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Viking Therapeutics in a research report on Wednesday, October 8th. Morgan Stanley lifted their price target on shares of Viking Therapeutics from $98.00 to $102.00 and gave the stock an &#34;overweight&#34; rating in a research note on Thursday, October 23rd. BTIG Research  restated a &#34;buy&#34; rating and issued a $125.00 price objective on shares of Viking Therapeutics in a research note on Monday, September 22nd. Cantor Fitzgerald  set a $105.00 price objective on Viking Therapeutics in a report on Thursday, October 23rd. Finally, HC Wainwright  reiterated a &#34;buy&#34; rating and set a $102.00 target price on shares of Viking Therapeutics in a research report on Monday, September 29th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned  a Buy rating, three have assigned  a Hold rating and one  has assigned  a Sell rating to the company. According to data from MarketBeat, Viking Therapeutics presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $87.14.</p><p><b>View Our Latest Research Report on VKTX</b></p><h2>About Viking Therapeutics</h2> (Free Report)<p>Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company's pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.  </p><p>The company's lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.</p><h2>See Also</h2><ul><li>Five stocks we like better than Viking Therapeutics</li><li>The Best $1 You'll Spend This Holiday Season</li><li>Holiday surprise: $1 gets you everything</li><li>America’s “most deplorable” Christmas sale</li><li>Do not delete, read immediately</li><li>Market Panic: Trump Just Dropped a Bomb on Your Stocks</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Viking Therapeutics Right Now?</h2><p>Before you consider Viking Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.</p><p>While Viking Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

VKTX

VOYA

<p>Voya Investment Management LLC significantly reduced its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX) by 91.9% in Q3, now holding 26,797 shares valued at $704,000. Other institutional investors have also made moves, with 76.03% of the stock owned by hedge funds. Viking's stock opened at $35.18, with a market cap of $3.98 billion. The company reported a loss of $0.81 EPS for the last quarter, missing estimates. Insider trading included significant sales by the director and CFO. Analysts have mixed ratings, with a consensus of "Moderate Buy" and a target price of $87.14.</p>

Viking Therapeutics, Inc. $VKTX Shares Sold by Voya Investment Management LLC